Basic characteristics of 446 HC and 400 AML patients in training and validation sets
| Variable . | Training set . | Validation set . | P value for difference between training and validation sets* . | ||||
|---|---|---|---|---|---|---|---|
| HC (n = 260) . | AML (n = 229) . | P value* . | HC (n = 186) . | AML (n = 171) . | P value* . | ||
| Age, years | .11 | .45 | .19 | ||||
| Median | 44.00 | 47.00 | 45.00 | 47.00 | |||
| Range | 17-82 | 15-82 | 24-76 | 15-89 | |||
| Gender, no. (%) | .90 | .16 | .94 | ||||
| Male | 153 (58.85) | 136 (59.39) | 116 (62.37) | 94 (54.97) | |||
| Female | 107 (41.15) | 93 (40.61) | 70 (37.63) | 77 (45.03) | |||
| ALT, U/L | .63 | .06 | .75 | ||||
| Median | 21.00 | 22.00 | 22.00 | 19.50 | |||
| Range | 10.00-166.00 | 5.00-459.00 | 9.00-76.00 | 3.00-288.00 | |||
| AST, U/L | .01 | .23 | .49 | ||||
| Median | 21.00 | 24.00 | 22.00 | 21.00 | |||
| Range | 13.00-55.00 | 3.00-607.00 | 12.00-43.00 | 3.00-348.00 | |||
| Serum creatinine groups, no.† | — | .30 | .88 | ||||
| ≤230 μmol/L | 260 | 229 | 186 | 170 | |||
| >230 μmol/L | 0 | 0 | 0 | 1 | |||
| Hepatic or renal function, no.‡ | .07 | .07 | .59 | ||||
| Normal | 259 | 224 | 186 | 168 | |||
| Abnormal | 1 | 5 | 0 | 3 | |||
| WBC, 109/L | .55 | ||||||
| Median | 8.00 | 7.30 | |||||
| Range | 0.10-292.20 | 0.08-290.00 | |||||
| Platelet, 109/L | .72 | ||||||
| Median | 39.00 | 37.00 | |||||
| Range | 4.00-500.00 | 2.00-899.00 | |||||
| BM blasts, % | .53 | ||||||
| Median | 66.00 | 65.00 | |||||
| Range | 20.00-99.00 | 18.00-97.00 | |||||
| Cytogenetics, no. (%) | .24 | ||||||
| t(15;17)/PML-RARA | 38 (16.59) | 19 (11.11) | |||||
| t(8;21)/AML1-ETO | 28 (12.23) | 19 (11.11) | |||||
| inv(16;16)/CBFβ-MYH11 | 7 (3.06) | 12 (7.02) | |||||
| CN-AML§ | 148 (64.63) | 115 (67.25) | |||||
| Unfavorable|| | 8 (3.49) | 6 (3.51) | |||||
| Variable . | Training set . | Validation set . | P value for difference between training and validation sets* . | ||||
|---|---|---|---|---|---|---|---|
| HC (n = 260) . | AML (n = 229) . | P value* . | HC (n = 186) . | AML (n = 171) . | P value* . | ||
| Age, years | .11 | .45 | .19 | ||||
| Median | 44.00 | 47.00 | 45.00 | 47.00 | |||
| Range | 17-82 | 15-82 | 24-76 | 15-89 | |||
| Gender, no. (%) | .90 | .16 | .94 | ||||
| Male | 153 (58.85) | 136 (59.39) | 116 (62.37) | 94 (54.97) | |||
| Female | 107 (41.15) | 93 (40.61) | 70 (37.63) | 77 (45.03) | |||
| ALT, U/L | .63 | .06 | .75 | ||||
| Median | 21.00 | 22.00 | 22.00 | 19.50 | |||
| Range | 10.00-166.00 | 5.00-459.00 | 9.00-76.00 | 3.00-288.00 | |||
| AST, U/L | .01 | .23 | .49 | ||||
| Median | 21.00 | 24.00 | 22.00 | 21.00 | |||
| Range | 13.00-55.00 | 3.00-607.00 | 12.00-43.00 | 3.00-348.00 | |||
| Serum creatinine groups, no.† | — | .30 | .88 | ||||
| ≤230 μmol/L | 260 | 229 | 186 | 170 | |||
| >230 μmol/L | 0 | 0 | 0 | 1 | |||
| Hepatic or renal function, no.‡ | .07 | .07 | .59 | ||||
| Normal | 259 | 224 | 186 | 168 | |||
| Abnormal | 1 | 5 | 0 | 3 | |||
| WBC, 109/L | .55 | ||||||
| Median | 8.00 | 7.30 | |||||
| Range | 0.10-292.20 | 0.08-290.00 | |||||
| Platelet, 109/L | .72 | ||||||
| Median | 39.00 | 37.00 | |||||
| Range | 4.00-500.00 | 2.00-899.00 | |||||
| BM blasts, % | .53 | ||||||
| Median | 66.00 | 65.00 | |||||
| Range | 20.00-99.00 | 18.00-97.00 | |||||
| Cytogenetics, no. (%) | .24 | ||||||
| t(15;17)/PML-RARA | 38 (16.59) | 19 (11.11) | |||||
| t(8;21)/AML1-ETO | 28 (12.23) | 19 (11.11) | |||||
| inv(16;16)/CBFβ-MYH11 | 7 (3.06) | 12 (7.02) | |||||
| CN-AML§ | 148 (64.63) | 115 (67.25) | |||||
| Unfavorable|| | 8 (3.49) | 6 (3.51) | |||||
ALT, alanine aminotransferase; AST, aspartate aminotransferase; WBC, white blood cell.
P values were calculated by means of nonparametric Wilcoxon rank-sum test for continuous variables and χ-square test for categorical variables. — indicates not applicable.
230 μmol/L is equal to 2× normal value.
Hepatic abnormality as defined by ALT >2.5×normal value or AST >2.5× normal value, while renal abnormality as defined by creatinine >2.5× normal value.
CN-AML: cases having no cytogenetically identifiable abnormalities.
Unfavorable: inv(3)/t(3;3), t(9;22), 11q23 abnormalities, −5, −7, del(5q),del(7p), and complex karyotype.